Cervelo is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate.

More on Cervelo

CPL7075 is an oral drug candidate with analgesic and anti-inflammatory properties targeted at neuropathic and inflammatory pain, and inflammation. First in class, CPL7075 may represent a much safer and tolerable, as well as novel efficacious treatment for neuropathic and inflammatory pain as well as inflammation.

More on CPL7075